EC grants approval for AbbVie’s Skyrizi to treat Crohn’s disease

Title: EC Grants Approval for AbbVie’s Skyrizi to Treat Crohn’s Disease


In a significant development for patients suffering from Crohn’s disease, the European Commission (EC) has recently granted approval for AbbVie’s groundbreaking treatment called Skyrizi. This milestone represents a significant step forward in improving the lives of individuals living with this chronic inflammatory bowel disease. In this blog post, we will explore the key points surrounding the EC’s approval of Skyrizi for the treatment of Crohn’s disease and discuss the potential impact on patients and healthcare providers.

Key Points:

  1. Overview of Crohn’s Disease:
    Crohn’s disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract. It causes symptoms such as abdominal pain, diarrhea, fatigue, and weight loss. Managing the disease involves controlling inflammation to prevent flare-ups and maintain remission. Treatment options often include medications, lifestyle changes, and, in severe cases, surgical interventions.
  2. Introduction of Skyrizi:
    Skyrizi, developed by AbbVie, is a novel treatment that was originally approved for psoriasis. The EC’s recent approval expands its indication for the treatment of Crohn’s disease. Skyrizi belongs to a class of medications known as interleukin inhibitors, specifically targeting interleukin-23 (IL-23), a protein involved in the immune response. By inhibiting IL-23, Skyrizi can help reduce inflammation in the gut, thus providing relief for individuals with Crohn’s disease.
  3. Efficacy and Safety Profile:
    The approval of Skyrizi for Crohn’s disease is based on successful clinical trials that demonstrated its efficacy in significantly reducing symptoms and inducing and maintaining remission. In these studies, Skyrizi showcased its ability to decrease inflammation and improve patients’ quality of life. Moreover, the treatment displayed a favorable safety profile, with adverse events generally being mild to moderate in severity.
  4. Potential Benefits for Patients:
    The EC’s approval of Skyrizi offers new hope for individuals living with Crohn’s disease. The treatment’s efficacy in reducing symptoms and inducing remission can lead to significant improvements in patients’ overall well-being, including relief from abdominal pain, decreased frequency of bowel movements, and increased energy levels. By effectively managing the disease, Skyrizi may enhance patients’ ability to engage in everyday activities.
  5. Considerations for Healthcare Providers:
    With the availability of Skyrizi, healthcare providers now have an additional tool to address the complex challenges associated with Crohn’s disease. They can work closely with patients to evaluate the appropriateness of Skyrizi and other treatment options based on individual circumstances, disease severity, and potential benefits and risks. Additionally, healthcare providers can monitor patients using regular assessments and adjust treatment plans as needed to optimize outcomes.
  6. Impact on Crohn’s Disease Management:
    The approval of Skyrizi represents a significant advancement in the management of Crohn’s disease. By specifically targeting IL-23, Skyrizi offers a tailored therapeutic approach to tackling the underlying inflammation in the gut. This innovation expands the treatment landscape, providing additional options for patients who may not have responded adequately to other therapies. The availability of Skyrizi may also contribute to reducing the need for more invasive interventions or surgical procedures to manage the disease.


The EC’s approval of AbbVie’s Skyrizi for the treatment of Crohn’s disease marks an important milestone in improving the lives of individuals living with this chronic inflammatory condition. Skyrizi’s unique mechanism of action, targeting IL-23, offers new hope for patients by effectively managing inflammation and providing symptom relief. The availability of this treatment option expands the choices available to healthcare providers, allowing them to tailor treatment plans based on individual needs. As Skyrizi becomes more accessible, it has the potential to positively impact the management of Crohn’s disease and enhance the quality of life for patients.